Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Microbiome of the Eye01:22

Microbiome of the Eye

The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body Composition and Body Mass Index Show Comparable Associations with Adalimumab Exposure and Immunogenicity in Noninfectious Uveitis.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same author

A Case Report of Presumed West Nile Virus Chorioretinitis in a Non-Endemic Area: Atypical Serology and Imaging Features of Old and New Lesions.

Case reports in ophthalmology·2026
Same author

Levofloxacin/ketorolac combination versus levofloxacin alone for topically treating moderate-severe acute bacterial conjunctivitis: a randomized controlled trial.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Retinal macrophage-like cell activation and ganglion cell layer thinning are associated with disability and MRI lesion burden in multiple sclerosis.

PloS one·2026
Same author

Thyroid hormone regulatory system in the mouse retina: integrated transcriptional and translational analysis of deiodinase enzymes, thyroid hormone receptors and thyroid hormone transporters.

Cell communication and signaling : CCS·2026
Same author

Two-years efficacy and safety of bleb forming devices in uncontrolled glaucoma.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same journal

Probe-assisted ILM-Rhexis: A Novel Peeling Technique.

Journal of ophthalmic & vision research·2026
Same journal

Full-thickness Macular Hole Formation and Spontaneous Closure Following Vitrectomy Surgery: A Case Report and Review of the Literature.

Journal of ophthalmic & vision research·2026
Same journal

Anterior Segment Eye Diseases and Quality of Life: An Updated Comprehensive Narrative Review.

Journal of ophthalmic & vision research·2026
Same journal

Quality of Life in Patients with Posterior Segment Eye Diseases.

Journal of ophthalmic & vision research·2026
Same journal

Emerging Roles of Regulated Cell Death-mediated Inflammation in Pathophysiology of Ocular Diseases.

Journal of ophthalmic & vision research·2026
Same journal

Early Diagnosis of Glaucoma By Optical Coherence Tomography: A Systematic Review and Network Meta-analysis.

Journal of ophthalmic & vision research·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

Biologic agents in inflammatory eye disease.

Chiara Posarelli1, Ilir Arapi, Michele Figus

  • 1Department of Neurosciences, Ophthalmology, University of Pisa, Pisa, Italy.

Journal of Ophthalmic & Vision Research
|March 29, 2012
PubMed
Summary
This summary is machine-generated.

Biologic agents offer new hope for treating non-infectious uveitis, a sight-threatening condition. While effective in many cases, further randomized trials are needed to optimize their use and address cost and safety concerns.

Keywords:
Biologic AgentImmunosuppressionUveitis

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Related Experiment Videos

Last Updated: May 23, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Area of Science:

  • Ophthalmology
  • Immunology
  • Rheumatology

Background:

  • Non-infectious uveitis is a serious ocular condition that can lead to vision loss.
  • Traditional treatments include steroids and immunosuppressants, but some cases are refractory.
  • Biologic agents represent a significant advancement in managing inflammatory eye diseases.

Purpose of the Study:

  • To review current literature on the use of biologic agents for treating non-infectious uveitis.
  • To evaluate the efficacy and safety of biologics in refractory uveitis cases.
  • To identify gaps in evidence, particularly the need for randomized controlled trials.

Main Methods:

  • Review of existing scientific literature on biologic therapies for uveitis.
  • Analysis of reports on tumor necrosis factor blockers, anti-interleukins, and interferon alpha.
  • Assessment of reported efficacy, safety profiles, and limitations of current evidence.

Main Results:

  • Biologic therapies have shown promise in controlling various forms of refractory uveitis.
  • These agents offer improved treatment options and the potential for long-term remission.
  • Evidence from randomized controlled trials is limited for most biologic applications in uveitis.

Conclusions:

  • Biologics represent a promising therapeutic class for non-infectious uveitis with a generally favorable profile.
  • Further research, including randomized controlled trials, is crucial to guide treatment decisions.
  • High costs and potential complications necessitate careful consideration of biologic use in refractory cases.